Loading...
Market
Will Monte Rosa's stock price rise by 20% or more by Jan 31, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock price data from financial markets
Story
Monte Rosa Therapeutics Announces $150M Global License Agreement with Novartis
Oct 28, 2024, 10:30 AM
Monte Rosa Therapeutics ($GLUE) has announced a global license agreement with Novartis ($NVS) to advance T and B Cell-modulating VAV1-directed molecular glue degraders. The deal includes $150 million upfront and potential payments up to $2.1 billion. This agreement aims to enhance Monte Rosa's capabilities in the field of targeted protein degradation, competing with companies like Kymera Therapeutics.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Over $2 billion • 25%
Yes • 50%
No • 50%
New partnership with a major pharma • 25%
Expansion of existing partnerships • 25%
No new partnership • 25%
Acquisition by another company • 25%
